Eli Lilly (LLY) has been in the news on several fronts lately, showcasing its strength in the bio-tech market. The company's weekly dosing drug,
Insulin Efsitora Alfa, has delivered consistent A1C reduction along with a safety profile. Other positive announcements include the acquisition of a new injectable medicine manufacturing facility from
Nexus Pharmaceuticals, and striking a deal to fight counterfeit diabetes and weight-loss drugs,
Mounjaro and
Zepbound.
Financial results have also been steadily positive with LLY stock increasing despite market slips and hikes in full-year guidance due to strong sales of Zepbound and Mounjaro. This performance indicates a buy situation for Eli Lilly. Finally, a deal with
Cipla for partnership in India is being negotiated. Downside factors are few but include a delay in FDA decision on Donanemab and a caution that the stock may be overvalued.
Eli Lilly LLY News Analytics from Fri, 22 Dec 2023 08:00:00 GMT to Thu, 16 May 2024 14:13:00 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor -5
